The PE Ratio as of September 2024 (TTM) for Cyclacel Pharmaceuticals, Inc. (CYCC) is -0.07

According to Cyclacel Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.07. This represents a change of -62.28% compared to the average of -0.19 of the last 4 quarters.

Cyclacel Pharmaceuticals, Inc. (CYCC) Historical PE Ratio (quarterly & annually)

How has CYCC PE Ratio performed in the past?

The mean historical PE Ratio of Cyclacel Pharmaceuticals, Inc. over the last ten years is -10.07. The current -0.07 PE Ratio has changed -30.48% with respect to the historical average. Over the past ten years (40 quarters), CYCC's PE Ratio was at its highest in in the December 2023 quarter at -0.11. The PE Ratio was at its lowest in in the March 2021 quarter at -53.73.

Cyclacel Pharmaceuticals, Inc. (CYCC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cyclacel Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cyclacel Pharmaceuticals, Inc. (CYCC) Average PE Ratio

How has CYCC PE Ratio performed in the past?

The current PE Ratio of Cyclacel Pharmaceuticals, Inc. (CYCC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cyclacel Pharmaceuticals, Inc. (CYCC) PE Ratio vs. Peers

How is CYCC’s PE Ratio compared to its peers?

Cyclacel Pharmaceuticals, Inc.’s PE Ratio is greater than Eliem Therapeutics, Inc. (-3.90), greater than Ikena Oncology, Inc. (-1.24), greater than Ovid Therapeutics Inc. (-2.73), greater than Connect Biopharma Holdings Limited (-2.86), greater than Edgewise Therapeutics, Inc. (-13.69), greater than Rezolute, Inc. (-4.51), greater than Cyteir Therapeutics, Inc. (-3.52), greater than XOMA Corporation (-18.22), greater than Protagenic Therapeutics, Inc. (-0.56), greater than Tempest Therapeutics, Inc. (-0.96), less than OncoVista Innovative Therapies, Inc. (0), less than Neurobiological Technologies, Inc. (0), less than Polydex Pharmaceuticals Limited (0), less than Catalyst Biosciences, Inc. (0), greater than Moleculin Biotech, Inc. (-0.44), greater than Pulmatrix, Inc. (-0.25), greater than Akari Therapeutics, Plc (-0.69), greater than NextCure, Inc. (-1.60), greater than CytomX Therapeutics, Inc. (-0.59), less than Neoleukin Therapeutics, Inc. (9.30), greater than Spero Therapeutics, Inc. (-0.98), less than Assembly Biosciences, Inc. (4.17), greater than null (-2.21),

Build a custom stock screener for Cyclacel Pharmaceuticals, Inc. (CYCC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclacel Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cyclacel Pharmaceuticals, Inc. (CYCC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cyclacel Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.